Novo Nordisk will slash the U.S. list prices of its weight-loss and diabetes drugs Wegovy, Ozempic, and Rybelsus by up to 50% starting January 1, 2027. The new price will be $675 per month, a move driven by increasing competition in the GLP-1 drug market.
Comments